LONDON, February 28, 2013 /PRNewswire/ --
A new report by visiongain predicts that the world market for cell-based assays will reach $4.7bn in 2016. That forecast and others appear in Cell-Based Assays: World Market Prospects 2013-2023, published in February 2013.
The new study explains how increased application and improvement in detection technology will be the major drivers for the cell-based assay market. As more pharma companies outsource drug discovery and development, forming strategic partnerships with contract research providers (CROs), cell-based assay services will increase their share of the market from 24.5% in 2011 to 30.2% in 2023, the report shows. In terms of application, primary screening accounted for the largest share of the cell-based assay market in 2011, with sales of $1.05bn (43.6%).
Hemant Mistry, a pharmaceutical industry analyst in visiongain, said: "Advances in detection equipment, improving sensitivity in drug screening, will act as key drivers for the cell-based assay market, in addition to the increased demand for more relevant and accurate toxicity models that can be used early in drug development. Miniaturising and multiplexing cell-based assays will make drug discovery more efficient and cheaper, which will also drive market growth over coming years.
"In 2011, developed markets - such as the US, Japan and Western Europe - accounted for the majority of the cell-based assays revenue. Global market shares for those countries are not expected to change significantly over the forecast period, as much of the world's drug discovery and development occurs there. The US accounted for 44.0% of the market in 2011. Emerging markets, such as China and India, will also experience strong growth throughout the period 2013-2023, we predict. Growth will be driven by increased outsourcing and also the trend of major pharmaceutical companies moving R&D there.
"There are strong opportunities for the cell-based assays market to expand in line with the continued development of technology for miniaturisation and automation, which includes higher sensitivity detection systems. Furthermore, the increased emphasis on stem cells will help develop disease-relevant models, as well as an abundant supply of unmodified human cells. Greater use of label-free detection systems will also allow the use of unmodified cells, removing the need to insert reporter proteins that can affect cell function. Opportunities will also arise from trends within the pharmaceutical industry, such as the need for more-accurate toxicity data before clinical trials, and the greater demand for biological drugs. Those drug classes will increase demand for immunogenicity, comparative and neutralising antibody assays."
Visiongain's report shows revenue forecasts to 2023 at world market, submarket and national level. It forecasts the following submarkets:
That new study also analyses large CROs and other specialists in cell assaying products and services. Companies discussed include Covance, PPD, Charles River Laboratories, BD Biosciences and GE Healthcare.
The analysis explores technological trends. Also, it forecasts revenues in leading national markets: the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC).
Cell-Based Assays: World Market Prospects 2013-2023 adds to visiongain's range of analytical reports on industries and markets for pharmaceutical technologies.
For sample pages and further information concerning the visiongain report Cell-Based Assays: World Market Prospects 2013-2023, please visit: http://www.visiongain.com/Report/988/Cell-Based-Assays-World-Market-Prospects-2013-2023
Accuri Cytometers (now part of BD)
Agilent Automation Solutions
American Type Culture Collection (ATCC)
Apredica (now part of Cyprotex)
Aurigene Discovery Technologies (a subsidiary of Dr Reddy's Laboratories)
BD Biosciences (a division of Becton, Dickinson & Co - BD)
Beckman Coulter (now part of Danaher)
Becton, Dickinson & Co.
Caliper Discovery Alliances and Services (CDAS, a subsidiary of Caliper Life Sciences)
Caliper Life Sciences (now part of PerkinElmer)
Cellomics (now part of Thermo Fisher Scientific)
Cellular Dynamics International
Charles River Laboratories
Corning Life Sciences
Dr. Reddy's Laboratories
European Collection of Cell Cultures (ECACC)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Food and Drug Administration (US FDA)
GE Healthcare (a division of General Electric)
Harvard NeuroDiscovery Centre
Jubilant Life Sciences
Marin Biologic Laboratories
MDS Analytical Technologies (now part of Danaher)
Molecular Devices (a subsidiary of Danaher)
NovaScreen Biosciences (part of Caliper Life Sciences)
Proteome Sciences R&D
Q3DM (part of Beckman Coulter)
Radiometer (a subsidiary of Danaher)
Roche Applied Science (a division of Roche)
Sentigen Holding (part of Life Technologies)
Shionogi & Company
Stem Cell Innovations
The Automation Partnership
Thermo Fisher Scientific
Tumour Biology Center Freiburg
University of Kyoto
University of Michigan
World Trade Organization (WTO)
Xenogen Biosciences (formerly part of Caliper Life Sciences, acquired by Taconic in 2009)
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials and Automotive sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44(0)207-336-6100